In this episode of BioTales, we uncover the remarkable story of Skyhawk Therapeutics – a biotech company with its wings firmly set on the frontiers of RNA biology. From a chance meeting on a humanitarian trip that sparked a revolutionary vision, to billion‑dollar collaborations with pharma giants, Skyhawk’s journey reads like a biotech thriller. We dive into the science of RNA splicing, the trials of launching a startup, and the promise of first‑in‑class, orally available medicines for Huntin...
All content for BioTales - Every Biotech Has a Story is the property of Hurley Li and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
In this episode of BioTales, we uncover the remarkable story of Skyhawk Therapeutics – a biotech company with its wings firmly set on the frontiers of RNA biology. From a chance meeting on a humanitarian trip that sparked a revolutionary vision, to billion‑dollar collaborations with pharma giants, Skyhawk’s journey reads like a biotech thriller. We dive into the science of RNA splicing, the trials of launching a startup, and the promise of first‑in‑class, orally available medicines for Huntin...
In this episode of BioTales, we uncover the remarkable story of Skyhawk Therapeutics – a biotech company with its wings firmly set on the frontiers of RNA biology. From a chance meeting on a humanitarian trip that sparked a revolutionary vision, to billion‑dollar collaborations with pharma giants, Skyhawk’s journey reads like a biotech thriller. We dive into the science of RNA splicing, the trials of launching a startup, and the promise of first‑in‑class, orally available medicines for Huntin...
In this episode of BioTales, we dive into the creation of Interius BioTherapeutics, a company born from a physician’s frustration with traditional CAR-T therapy and propelled into the spotlight by an industry‑shaking acquisition: Gilead’s Kite decided to buy Interius for $350 million. We explore how a simple idea to turn the body into its own bioreactor led to a platform that might democratize gene therapy. Along the way we revisit the founding story of physician–scientist Saar Gill and biote...
This episode tells the extraordinary story of Halda Therapeutics, founded during the 2020 pandemic when renowned Yale professor Craig Crews gathered his team around an outdoor fireplace to brainstorm revolutionary cancer treatments. We explore Crews' journey as a serial biotech entrepreneur and his pioneering RIPTACs (Regulated Induced Proximity TArgeting Chimeras) at Halda -- a groundbreaking "hold and kill" approach that doesn't destroy cancer proteins but holds them hostage instead. The ep...
What happens when a group of veteran chemists decide to take on one of oncology’s most notorious challenges? In this episode of BioTales, we explore the remarkable journey of Kumquat Biosciences—a biotech startup whose audacious goal is to tame the “undruggable” KRAS mutations and to re‑imagine how small molecules can awaken the immune system. Through a narrative filled with scientific intrigue, boardroom gambits and the resilience of a tiny citrus fruit, we follow the company’s p...
This conversation explores the groundbreaking journey of SetPoint Medical, a company that aims to revolutionize the treatment of autoimmune diseases through neuroimmune modulation. Starting from a simple idea sketched on a napkin, the discussion delves into the science behind vagus nerve stimulation, the challenges of clinical trials, the importance of funding, and the recent FDA approval of their device for rheumatoid arthritis. The conversation highlights the potential for a paradigm shift ...
This conversation delves into Sitryx Therapeutics, a pioneering company in the field of immunometabolism, aiming to revolutionize the treatment of autoimmune diseases by targeting metabolic pathways in immune cells. The discussion covers the founding vision, the scientific basis of their approach, the development of drug candidates, strategic partnerships, and the broader implications for biotech innovation. The conversation emphasizes the importance of clinical data in validating their innov...
This conversation explores the groundbreaking advancements made by Capstan Therapeutics in the field of cell therapy, particularly focusing on their innovative approach to in vivo engineering and targeted lipid nanoparticles. The discussion highlights the company's rapid growth, significant funding, and the potential impact of their technology on treating autoimmune diseases. The conversation also addresses the challenges faced in the biotech industry and the future prospects for Capstan as t...
This conversation delves into the journey of Moonlake Immunotherapeutics, a biotech company that has rapidly gained recognition in the field of immunology. The discussion covers the founders' vision, the innovative science behind their lead drug Sonolokimab, the ambitious clinical trials they are undertaking, and the strategic financing that has supported their growth. The conversation highlights the potential impact of their work on the treatment of inflammatory diseases and the future prosp...
In this episode of BioTales, we uncover the remarkable story of Skyhawk Therapeutics – a biotech company with its wings firmly set on the frontiers of RNA biology. From a chance meeting on a humanitarian trip that sparked a revolutionary vision, to billion‑dollar collaborations with pharma giants, Skyhawk’s journey reads like a biotech thriller. We dive into the science of RNA splicing, the trials of launching a startup, and the promise of first‑in‑class, orally available medicines for Huntin...
